Xi Guo1,2†
Suyao Li1†
Hanxing Tong2,3Yong Zhang2,3Yuan Ji4Rongyuan Zhuang1,2Chenlu Zhang1,2Yang You1,2Weiqi Lu2,3*Yuhong Zhou1,2*- 1Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China
- 2Department of Clinic, Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, China
- 3Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China
- 4Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China
Background: Leiomyosarcoma (LMS) is a malignant smooth muscle neoplasm, in which the efficacy of immune checkpoint blockade (ICB) is very limited. What is worse, loss of PTEN, known as a negative factor for ICB, frequently occurred in LMS. Seeking new strategies for LMS patients harboring loss of PTEN is important and challenging.
Case Presentation: A 42-year-old Chinese male was diagnosed as having unresectable LMS of the iliopsoas. After the failure of two prior chemotherapy regimens, whole-exome sequencing revealed that tumor tissue had high tumor mutation burden (689 Muts), high microsatellite instability, and some somatic mutations, including PTEN (copy number loss and p.N323fs), MSH6 (p.F1088fs), TP53 p.R273C, ASXL1 p.G645fs, ATR p.S1843P, and CDKN2A p.A118P. Then, antiangiogenic agent (pazopanib or anlotinib) plus pembrolizumab was administered from January 2 to August 6, 2018. However, pazopanib was stopped on June 18 due to the grade 2/3 adverse effect of hand–foot skin reaction, and anlotinib was administered. Considering that the tumor shrunk after immunotherapy, he underwent radical resection on September 6, 2018. The final pathological diagnosis confirmed pathologic complete response (CR). Until the latest follow-up (September 15, 2021), no progressive disease was observed and total disease-free survival has exceeded 36 months.
Conclusion: We presented a patient with an unresectable mismatch repair (MMR)-deficient LMS harboring biallelic loss of PTEN who achieved CR from a combination strategy of antiangiogenesis plus pembrolizumab. Such a strategy might be a promising strategy to overcome the ICB resistance caused by the loss of PTEN. Such conclusions need to be further confirmed in further investigations.
Introduction
Leiomyosarcoma (LMS) is a malignant smooth muscle neoplasm that consists of about 15%–20% of soft tissue sarcomas (STSs) and frequently originates in sites of the uterus and retroperitoneum (1, 2). Currently, radical surgery is still the dominant curative modality for early-stage LMS. For unresectable or advanced LMS, chemotherapy is regarded as a standard strategy. Besides, antiangiogenesis agents, such as pazopanib and anlotinib, have also been proven effective in a variety of STSs (3–6).
Until now, immune checkpoint blockade (ICBs) is becoming a promising treatment strategy for various tumors. For example, pembrolizumab has brought significant clinical benefits for patients with microsatellite instability-high and/or mismatch repair deficient (MSI-H/dMMR) solid tumors in the pan-cancer cohort (7). Although promising, only one dMMR STS was included in the aforementioned cohort, and the patient, unfortunately, developed progressive disease. In another retrospective study, seven LMS patients treated with nivolumab were included. Noted that three patients achieved stable disease (SD), and no patient achieved partial response (PR) or complete response (CR) (8). To the best of our knowledge, only a few cases reported that patients with LMS could achieve a response to ICB alone (9). What is worse, loss of PTEN, known as a negative factor of ICBs, occurs frequently in LMS (2, 10, 11). Recently, some clinical trials explored the combination strategies of ICBs and antiangiogenesis to alleviate ICB resistance. For instance, the combination strategy of axitinib and pembrolizumab was explored in 30 patients with STS, including six LMS patients. The median progression-free survival (PFS) was 5.4 months, and the best objective response rate (ORR) was 21.9% (12). Taken together, the efficacy of ICB in LMS is minimal. Seeking novel immunotherapy strategies for LMS patients harboring loss of PTEN is still important and challenging. Herein, we firstly reported an unresectable LMS patient harboring biallelic PTEN loss who achieved CR after antiangiogenesis plus ICB.
Case Presentation
A 42-year-old Chinese male was admitted to Zhongshan Hospital in October 2017, who had presented right buttock numbness for 2 years. His performance status (PS) score was 1. Positron emission tomography/computed tomography (PET/CT) demonstrated a malignant tumor that involved both the right psoas major muscle and anterior iliac fossa (Figure 1A). The result of magnetic resonance imaging (MRI) suggested that the tumor size was 131.8 mm × 101.1 mm, which was consistent with that of PET/CT (Figure 1B). Finally, the patient was confirmed to have a pathologic diagnosis of cT2bNxM0, stage IIB LMS (Figures 2A–D). Considering that the huge mass had invaded the pelvic wall, surgical resection was not recommended. The patient was administered first-line chemotherapy of liposomal Adriamycin (60 mg, day 1, every 3 weeks) plus dacarbazine (750 mg, days 1–2, every 3 weeks). After failure, he was administered second-line treatment strategy of gemcitabine (1.3 g, days 1 and 8), docetaxel (130 mg, day 8, every 3 weeks), and pazopanib (400 mg, once a day) in December 2017. Unfortunately, progressive disease was still developed in January 2018. To search for potential treatment opportunities, tumor tissue DNA was subjected to a next-generation sequencing-based assay. The whole-exome sequencing (WES) results showed that the patient had a high tumor mutation burden (TMB; 689 Muts) and MSI-H. Besides, some cancer-related gene somatic mutations also occurred, including biallelic loss of PTEN (copy number loss and p. N323fs), MSH6 (F1088fs), TP53 p.R273C, ASXL1 p.G645fs, ATR p.S1843P, and CDKN2A p.A118P. The expression of protein MSH6 was significantly lower compared with those of other proteins (MLH1, MSH2, or PMS2) (Figures 2E–H). Immunohistochemical staining revealed that PD-1 expression was 2% positive in tumor cells, negative in the stroma (Figure 2I) and PD-L1(BP60001L, 28-8,SP142) expression was negative in tumor cells, 2% positive in the stroma (Figures 2J–L). After Multi-Disciplinary Treatment (MDT) discussion, the patient received antiangiogenesis (pazopanib or anlotinib) plus pembrolizumab from January 10 to August 6, 2018. Figures 3A–C showed that the tumor lesion shrunk under the treatment of pembrolizumab (200 mg every 3 weeks) plus pazopanib (400 mg once a day). However, pazopanib was stopped on June 18 due to the grade 2/3 adverse effect (AE) of hand–foot skin reaction. Subsequently, anlotinib (12 mg, days 1–14, every 3 weeks) was administered, and the tumor continued to shrink (Figure 3D). Other AEs during the whole treatment were grade 1 hair discoloration, on which no management was performed. The patient underwent radical resection of retroperitoneal sarcoma, repair of abdominal wall defect, and resection of small bowel mesentery on September 6, 2018. The operation site was marked with a titanium clip, and a biological patch was placed. As shown in Figures 4A–D, final pathological diagnosis results confirmed a pathologic complete response (pCR).
Figure 1 (A) Positron emission tomography/computed tomography (PET/CT). (B) Magnetic resonance imaging (MRI) demonstrated a malignant tumor involving both the right psoas major muscle and anterior iliac fossa.
Figure 2 (A–C) Biopsy pathology confirmed mismatch repair (MMR)-deficient leiomyosarcoma (LMS) and the expression of programmed cell death protein-1/programmed cell death-ligand 1(PD-1/PD-L1) using different antibodies. The pathological lesion was measured by H&E staining. (D) Strong positive response of alpha-smooth muscle actin (a-SMA). (E–H) Absence of MSH6 staining and positive staining for MLH1, MSH2, and PMS2 indicated MSH6 deficiency. (I) Immunohistochemistry findings for PD-1. (J–L) Immunohistochemistry findings for PD-L1 using BP60001L, 28-8, or SP142.
Figure 3 The changes of tumor lesion. (A) Before and after the treatment of antiangiogenesis and pembrolizumab for (B) 1 month, (C) 3 months, and (D) 6 months.
Figure 4 Surgical pathology confirmed a pathological complete response (pCR) in this patient and the timeline of interventions and outcomes. (A) A variable extent of coagulative tumoral necrosis. (B) Cholesterol crystals around the tumoral necrosis. (C) Collagen fibers around the periphery of tumoral necrosis. (D) Histiocytes and multinucleated giant cells in the tumor. The bottom panel shows clinical interventions and outcomes of the patient.
During the follow-up in March 2019, PET/CT results in Figure 5A indicated a high local metabolic activity, which implied a suspected lesion. And the CT scan (Figure 5B) was consistent with the PET/CT results. However, pathologic diagnosis for lesion analysis was unrealistic due to the existence of the pelvic wall bone and the biological patch. In view of the situation above, MDT assumed that the high metabolic activity might be attributed to the inflammatory reaction caused by the biological patch and recommended the patient’s close follow-up. Such supposition was confirmed in the subsequent follow-up, and no progressive disease was observed until the latest follow-up (September 15, 2021; Figure 5C). Currently, the total disease-free survival (DFS) has exceeded 36 months and the follow-up is still ongoing.
Figure 5 (A) Positron emission tomography/computed tomography (PET/CT) suggested a high local metabolic activity during the follow-up of March 2019. CT scans for the patient on (B) February 25 and (C) September 15, 2021.
Discussion
LMS is a malignant smooth muscle neoplasm that occurs frequently in the uterus, retroperitoneum, buttock, and so on (2, 13). LMS of the iliopsoas is rare and presents unique challenges in management, since it is relatively inaccessible surgically due to being close to the ureter, aorta, inferior vena cava, spine, and the iliac vessels (14). In this work, we firstly presented an unresectable patient with LMS of the iliopsoas who achieved CR to antiangiogenesis plus ICB. The final DFS has exceeded 36 months.
Antiangiogenesis, such as pazopanib and anlotinib, has demonstrated promising efficacy for the treatment of advanced STS. Pazopanib is an orally multitargeted receptor tyrosine kinase (RTK) inhibitor, involving vascular endothelial growth factor (VEGF) receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs), and c-kit (4). In a randomized phase III clinical trial (PALETTE), significantly better PFS was observed in the patients treated with pazopanib compared with placebo (4.6 vs. 1.6 months) (5). Pazopanib has been approved by the Food and Drug Administration (FDA) for STS. Similarly, anlotinib, another orally multitargeted RTK inhibitor, was also approved for STS in China (15). In a phase II clinical trial, 166 patients with advanced STS were enrolled, including malignant fibrous histiocytoma (MFH, N = 19), liposarcoma (LPS, N = 13), LMS (N = 26), synovial sarcoma (SS, N = 47), or other sarcomas (N = 30) (16). The median PFS was 5.63 months, and the ORR was 11.45%. Note that the ORR for LMS was 7.67%. In another phase IIB clinical trial, 233 patients were included who were randomized 2:1 to receive anlotinib (N = 158) or placebo (N = 75) (6). Anlotinib treatment significantly improved the median PFS relative to the control (6.27 vs. 1.47 months, p < 0.0001). For LMS (N = 41), a similar result was observed (median PFS, 5.83 months vs. 1.43 months, p < 0.0001).
Recently, ICBs are becoming another promising treatment strategy for various tumors. However, LMS is usually regarded as a “cold tumor”, and ICBs are not applicable. It was reported that LMS was more common among patients who are immunosuppressive such as allograft transplantation receivers and HIV-infected patients (17). In SARC028, 10 LMS patients were enrolled to test the efficacy of single-agent pembrolizumab and no patient responded (18). Additionally, in Alliance A091401 study, 14 STS patients treated with nivolumab and ipilimumab were included (19). Confirmed responses were seen in patients with uterine LMS (N = 1) and non-uterine LMS (N = 1). What is worse, loss of PTEN might contribute to the ICB treatment resistance, which is frequently downregulated in LMS (2, 10, 11). Previous works suggested that loss of PTEN is usually caused by gene mutation, deletion, transcriptional silencing, or protein instability (20). Tumors with biallelic PTEN loss had significantly lower levels of mRNA expression of PDCD1, CD8A, IFNG, PRF1, and GZMA compared to PTEN-wild-type tumors (p < 0.05 for all) (11, 21).
Recently, some clinical trials explored the combination strategies of ICBs and antiangiogenesis treatment to alleviate the ICB resistance. Such synergistic effect has obtained some exciting outcomes in some tumors, such as advanced clear cell renal cell carcinoma and gastric or colorectal cancer (22–24). As for STSs, the combination strategy of axitinib and pembrolizumab was also explored in 30 STS patients, including alveolar soft part sarcoma(36%), undifferentiated pleomorphic sarcoma (15%), LMS (18%), other (30%). In the whole cohort, the median PFS was 5.4 months and the best ORR was 21.9% (12). In the present case, an unresectable LMS patient harboring biallelic loss of PTEN achieved CR to antiangiogenesis plus pembrolizumab. The dMMR/MSI-H and TMB-H may provide a potential mechanism for the successful management of the LMS. Though MMR deficiency occurs infrequently in LMS, it has been reported in some studies, and the MMR-deficient status points to some LMS patients as potentially sensitive to immunotherapy (25–27). However, in a clinical trial of pembrolizumab, one dMMR sarcoma patient enrolled still developed progressive disease (7). In KEYNOTE-158 study, which recruited 233 patients with advanced non-colorectal dMMR cancer, ORR was only 34.3% (28). So, for dMMR LMS patients who do not respond well to ICB, identifying genomic features through WES and taking genetic and epigenetic characteristics into consideration may be helpful (29). When somatic mutations like PTEN were detected, combination therapy with ICB may be more effective. Whether such combination strategy could overcome the resistance caused by the loss of PTEN is another important issue. Previous works suggested that loss of PTEN could result in unopposed Phosphatidylinositol-3 kinase (PI3K) activity and subsequently promote the VEGF expression on endothelial cells, which was regarded as a key tumor-associated factor that induces changes in blood vessel permeability and architecture (10). Hegde et al. (30) reported that anti-VEGF could contribute to reprogramming the tumor milieu from an immunosuppressive to an immune permissive microenvironment (30, 31). This case highlighted that antiangiogenesis might be an optimal combination partner for ICBs, and such a combination strategy might be a promising strategy for dMMR LMS, even for LMS harboring biallelic loss of PTEN. The exact mechanism should be explored in further exploration.
Conclusion
Taken together, this is the first report related to an antiangiogenic agent plus pembrolizumab in an unresectable dMMR LMS harboring biallelic loss of PTEN. The combination strategy of ICB plus antiangiogenesis might be a promising strategy to overcome the resistance caused by the loss of PTEN. Such conclusions need to be further confirmed in further investigations.
Data Availability Statement
The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding authors.
Ethics Statement
The studies involving human participants were reviewed and approved by the Ethics Committee of Zhongshan Hospital of Fudan University. The patients/participants provided their written informed consent to participate in this study.
Author Contributions
XG, SL, HT, YZ and YJ collected the clinical information, diagnostic information, therapeutic information, and images of the patients. XG and SL wrote the article. SL and CZ identified the case and submitted the article. RZ and YY revised the article. YHZ and WL proofread the article. XG and SL have contributed equally to this work. All authors contributed to the article and approved the submitted version.
Funding
This study was supported by the Beijing Xisike Clinical Oncology Research Foundation (No. Y-sy2018-148).
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Acknowledgments
We appreciate our patient and his family and our colleagues at Shanghai Zhongshan Hospital who supported us in the preparation of this article. All authors read and approved the final article.
References
1. Serrano C, George S. Leiomyosarcoma. Hematol Oncol Clin North Am (2013) 27(5):957–74. doi: 10.1016/j.hoc.2013.07.002
2. Grossmann AH, Layfield LJ, Randall RL. Classification, Molecular Characterization, and the Significance of Pten Alteration in Leiomyosarcoma. Sarcoma (2012) 2012:380896. doi: 10.1155/2012/380896
3. Yen CC, Chen TW. Next Frontiers in Systemic Therapy for Soft Tissue Sarcoma. Chin Clin Oncol (2018) 7(4):43. doi: 10.21037/cco.2018.08.04
4. Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schöffski P, et al. Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC Study 62043). J Clin Oncol: Off J Am Soc Clin Oncol (2009) 27(19):3126–32. doi: 10.1200/jco.2008.21.3223
5. van der Graaf WTA, Blay J-Y, Chawla SP, Kim D-W, Bui-Nguyen B, Casali PG, et al. Pazopanib for Metastatic Soft-Tissue Sarcoma (PALETTE): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial. Lancet (2012) 379(9829):1879–86. doi: 10.1016/s0140-6736(12)60651-5
6. Chi Y, Yao Y, Wang S, Huang G, Cai Q, Shang G, et al. Anlotinib for Metastasis Soft Tissue Sarcoma: A Randomized, Double-Blind, Placebo-Controlled and Multi-Centered Clinical Trial. J Clin Oncol (2018) 36(15_suppl):11503. doi: 10.1200/JCO.2018.36.15_suppl.11503
7. Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch Repair Deficiency Predicts Response of Solid Tumors to PD-1 Blockade. Science (2017) 357(6349):409–13. doi: 10.1126/science.aan6733
8. Paoluzzi L, Cacavio A, Ghesani M, Karambelkar A, Rapkiewicz A, Weber J, et al. Response to Anti-PD1 Therapy With Nivolumab in Metastatic Sarcomas. Clin Sarcoma Res (2016) 6:24. doi: 10.1186/s13569-016-0064-0
9. Heine A, Kristiansen G, Schild HH, Brossart P. Successful Treatment of Refractory Leiomyosarcoma With the PD-1 Inhibitor Nivolumab. Ann Oncol (2016) 27(9):1813–4. doi: 10.1093/annonc/mdw243
10. Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, et al. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov (2016) 6(2):202–16. doi: 10.1158/2159-8290.CD-15-0283
11. George S, Miao D, Demetri GD, Adeegbe D, Rodig SJ, Shukla S, et al. Loss of PTEN Is Associated With Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity (2017) 46(2):197–204. doi: 10.1016/j.immuni.2017.02.001
12. Wilky BA, Trucco MM, Kolonias D, Wieder E, Subhawong T, Rosenberg A, et al. A Phase II Trial of Axitinib Plus Pembrolizumab for Patients With Advanced Alveolar Soft Part Sarcoma (ASPS) and Other Soft Tissue Sarcomas (STS). J Clin Oncol (2018) 36(15_suppl):11547. doi: 10.1200/JCO.2018.36.15_suppl.11547
13. M’Liss M, Landry M, Sarma DP, Boucree JB Jr. Leiomyosarcoma of the Buttock. J Am Acad Dermatol (1991) 24(4):618–20. doi: 10.1016/0190-9622(91)70094-i
14. Mehta CR, Liu L, Theuer C. An Adaptive Population Enrichment Phase III Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma (TAPPAS Trial). Ann Oncol (2019) 30(1):103–8. doi: 10.1093/annonc/mdy464
15. Shen G, Zheng F, Ren D, Du F, Dong Q, Wang Z, et al. Anlotinib: A Novel Multi-Targeting Tyrosine Kinase Inhibitor in Clinical Development. J Hematol Oncol (2018) 11(1):120. doi: 10.1186/s13045-018-0664-7
16. Chi Y, Sun Y, Cai J, Yao Y, Hong X, Fang Z, et al. Phase II Study of Anlotinib for Treatment of Advanced Soft Tissues Sarcomas. J Clin Oncol (2016) 34(15_suppl):11005. doi: 10.1200/JCO.2016.34.15_suppl.11005
17. Bhatia K, Shiels MS, Berg A, Engels EA. Sarcomas Other Than Kaposi Sarcoma Occurring in Immunodeficiency: Interpretations From a Systematic Literature Review. Curr Opin Oncol (2012) 24(5):537–46. doi: 10.1097/CCO.0b013e328355e115
18. Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, et al. Pembrolizumab in Advanced Soft-Tissue Sarcoma and Bone Sarcoma (SARC028): A Multicentre, Two-Cohort, Single-Arm, Open-Label, Phase 2 Trial. Lancet Oncol (2017) 18(11):1493–501. doi: 10.1016/s1470-2045(17)30624-1
19. D’Angelo SP, Mahoney MR, Van Tine BA, Atkins J, Milhem MM, Jahagirdar BN, et al. Nivolumab With or Without Ipilimumab Treatment for Metastatic Sarcoma (Alliance A091401): Two Open-Label, Non-Comparative, Randomised, Phase 2 Trials. Lancet Oncol (2018) 19(3):416–26. doi: 10.1016/s1470-2045(18)30006-8
20. Stefano S, Giovanni S. The PTEN Tumor Suppressor Gene in Soft Tissue Sarcoma. Cancers (Basel) (2019) 11(8):1169. doi: 10.3390/cancers11081169
21. Vidotto T, Melo CM, Castelli E, Koti M, Dos Reis RB, Squire JA. Emerging Role of PTEN Loss in Evasion of the Immune Response to Tumours. Br J Cancer (2020) 122(12):1732–43. doi: 10.1038/s41416-020-0834-6
22. Choueiri TK, Larkin J, Oya M, Thistlethwaite F, Martignoni M, Nathan P, et al. Preliminary Results for Avelumab Plus Axitinib as First-Line Therapy in Patients With Advanced Clear-Cell Renal-Cell Carcinoma (JAVELIN Renal 100): An Open-Label, Dose-Finding and Dose-Expansion, Phase 1b Trial. Lancet Oncol (2018) 19(4):451–60. doi: 10.1016/S1470-2045(18)30107-4
23. Yi M, Jiao D, Qin S, Chu Q, Wu K, Li A. Synergistic Effect of Immune Checkpoint Blockade and Anti-Angiogenesis in Cancer Treatment. Mol Cancer (2019) 18(1):60. doi: 10.1186/s12943-019-0974-6
24. Fukuoka S, Hara H, Takahashi N, Kojima T, Kawazoe A, Asayama M, et al. Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, Epoc1603). J Clin Oncol: Off J Am Soc Clin Oncol (2020) 38(18):2053–61. doi: 10.1200/JCO.19.03296
25. Cohen JE, Eleyan F, Zick A, Peretz T, Katz D. Intratumoral Immune-Biomarkers and Mismatch Repair Status in Leiyomyosarcoma-Potential Predictive Markers for Adjuvant Treatment: A Pilot Study. Oncotarget (2018) 9:30847–54. doi: 10.18632/oncotarget.25747
26. Risinger JI, Umar A, Boyer JC, Evans AC, Berchuck A, Kunkel TA, et al. Microsatellite Instability in Gynecological Sarcomas and in Hmsh2 Mutant Uterine Sarcoma Cell Lines Defective in Mismatch Repair Activity. Cancer Res (1995) 55:5664–9.
27. Wang YJ, Williams HR, Brzezinska BN, Gaidis A, Patel B, Munroe J, et al. Use of Pembrolizumab in Msi-High Uterine Leiomyosarcoma; a Case Report and Review of the Literature. Gynecol Oncol Rep (2021) 35:100701. doi: 10.1016/j.gore.2021.100701
28. Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase Ii Keynote-158 Study. J Clin Oncol (2020) 38:1–10. doi: 10.18632/oncotarget.28032
29. Hasan NM, Sharma A, Ruzgar NM, Deshpande H, Olino K, Khan S, et al. Epigenetic signatures differentiate uterine and soft tissue leiomyosarcoma. Oncotarget (2021) 12:1566–79. doi: 10.18632/oncotarget.28032
30. Hegde PS, Wallin JJ, Mancao C. Predictive Markers of Anti-VEGF and Emerging Role of Angiogenesis Inhibitors as Immunotherapeutics. Semin Cancer Biol (2018) 52(Pt 2):117–24. doi: 10.1016/j.semcancer.2017.12.002
Keywords: leiomyosarcoma, PTEN, antiangiogenesis, immune checkpoint blockade, immunotherapy combined therapy
Citation: Guo X, Li S, Tong H, Zhang Y, Ji Y, Zhuang R, Zhang C, You Y, Lu W and Zhou Y (2022) Case Report: Complete Response to Antiangiogenesis and Immune Checkpoint Blockade in an Unresectable MMR-Deficient Leiomyosarcoma Harboring Biallelic Loss of PTEN. Front. Oncol. 12:802074. doi: 10.3389/fonc.2022.802074
Received: 26 October 2021; Accepted: 13 January 2022;
Published: 14 February 2022.
Edited by:
Riccardo Dolcetti, Peter MacCallum Cancer Centre, AustraliaReviewed by:
Antonia Digklia, Centre Hospitalier Universitaire Vaudois (CHUV), SwitzerlandAllie Grossmann, The University of Utah, United States
Copyright © 2022 Guo, Li, Tong, Zhang, Ji, Zhuang, Zhang, You, Lu and Zhou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yuhong Zhou, emhvdS55dWhvbmdAenMtaG9zcGl0YWwuc2guY24=; Weiqi Lu, bHUud2VpcWlAenMtaG9zcGl0YWwuc2guY24=
†These authors have contributed equally to this work